This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with
hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who require
parenteral iron infusions or blood transfusions. A total of 159 patients will be randomized
2:1 to treatment with oral pomalidomide or matching placebo for 24 weeks. Mean change from
baseline to 24 weeks in the Epistaxis Severity Score (ESS) will be compared between treatment
groups to determine pomalidomide efficacy.